The Infectious Diseases Clinical Research Consortium has begun enrolling up to 1,000 pregnant and postpartum individuals who have or will receive COVID-19 vaccine in a study to assess vaccine safety, immune response and transfer of antibodies to their infants, the National Institutes of Health announced yesterday. The study will enroll individuals up to two months postpartum, and follow participants and their infants through the first year after delivery.

“Tens of thousands of pregnant and breastfeeding people in the United States have chosen to receive the COVID-19 vaccines available under emergency use authorization,” said Anthony Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases “However, we lack robust, prospective clinical data on vaccination in these populations. The results of this study will fill gaps in our knowledge and help inform policy recommendations and personal decision-making on COVID-19 vaccination during pregnancy and in the postpartum period.”
 

Related News Articles

Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The National Institutes of Health Sept. 16 announced it has launched a consortium to help reduce preventable stillbirths across the U.S. The NIH said…
Headline
A blog by Julia Resnick, AHA senior director of health outcomes and care transformation, describes a new project with the Commonwealth Fund that will explore…